Clinical Study

Phase II/III Biomarker-Driven Master Protocol For Second Line Therapy Of Squamous Cell Lung Cancer (Screening Step).

Posted Date: Sep 21, 2017

  • Investigator: John Morris
  • Co-Investigator: Lauren Hendricks
  • Specialties: Hematology/Oncology, Oncology, Cancer, Lung Cancer
  • Type of Study: Drug

The purpose of the treatment part of this study is to compare the effects, good and bad, of these investigational agents to the usual approach to treating your type of cancer. It may be possible that you will not be able to participate in the treatment p

Criteria:

To Be Eligible For This Study, Patients Must Have Squamous Cell Lung Cancer.

Keywords:

Cancer, Lung Cancer, S1400, Squamous Cell, Null

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu

  • Search Clinical Studies

  • Research in the News

    Ride Cincinnati Gives $200,000 in Grants for Breast Cancer Research

    Marlene Harris-Ride Cincinnati has continued its support of UC Cancer Institutescientists with the annual award of five grants to continue promising breastcancer research.